Osteopore Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jing Lim

Chief executive officer

AU$202.2k

Total compensation

CEO salary percentage	91.8%
CEO tenure	4.6yrs
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	1.2yrs

Recent management updates

Recent updates

We Think Osteopore (ASX:OSX) Needs To Drive Business Growth Carefully

Aug 24

How Many Osteopore Limited (ASX:OSX) Shares Have Insiders Sold, In The Last Year?

Dec 29

CEO Compensation Analysis

How has Jing Lim's remuneration changed compared to Osteopore's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	AU$202k	AU$186k	-AU$5m
Sep 30 2023	n/a	n/a	-AU$5m
Jun 30 2023	n/a	n/a	-AU$5m
Mar 31 2023	n/a	n/a	-AU$5m
Dec 31 2022	AU$164k	AU$149k	-AU$4m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	n/a	n/a	-AU$4m
Mar 31 2022	n/a	n/a	-AU$4m
Dec 31 2021	AU$132k	AU$118k	-AU$4m
Sep 30 2021	n/a	n/a	-AU$3m
Jun 30 2021	n/a	n/a	-AU$3m
Mar 31 2021	n/a	n/a	-AU$2m
Dec 31 2020	AU$124k	AU$109k	-AU$2m
Sep 30 2020	n/a	n/a	-AU$2m
Jun 30 2020	n/a	n/a	-AU$2m
Mar 31 2020	n/a	n/a	-AU$2m
Dec 31 2019	AU$39k	AU$34k	-AU$2m

Compensation vs Market: Jing's total compensation ($USD131.83K) is below average for companies of similar size in the Australian market ($USD290.69K).

Compensation vs Earnings: Jing's compensation has increased whilst the company is unprofitable.

CEO

Jing Lim

4.6yrs

Tenure

AU$202,246

Compensation

Dr. Jing Lim, Ph. D. (Singapore), is Chief Executive Officer of Osteopore Limited from July 18, 2023 and serves as Chief Technology Officer May 01, 2022. Dr. Lim joined the Osteopore Limited on November 17...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kei Wei Leong	Executive Chairman	2.7yrs	AU$214.90k	0.12% A$ 4.9k
Jing Lim	CEO & CTO	4.6yrs	AU$202.25k	no data
Shu Voon	Financial Controller	1.3yrs	no data	no data
Khoon Seng Goh	Global Marketing Director	less than a year	AU$212.90k	0% A$ 0
Kellie Davis	Joint Company Secretary	1.3yrs	no data	no data

1.3yrs

Average Tenure

Experienced Management: OSX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kei Wei Leong	Executive Chairman	2.7yrs	AU$214.90k	0.12% A$ 4.9k
David Yeow	Member of Advisory Board	1.2yrs	no data	no data
Swee Hin Teoh	Non Executive Director	4.8yrs	AU$46.36k	5.75% A$ 234.7k
Daniel Ow	Independent Non-Executive Director	2.5yrs	AU$46.36k	no data
Greg Rudd	Member of Advisory Board	1.2yrs	no data	no data
Michael Wagels	Member of Advisory Board	1.2yrs	no data	no data
Joy Song	Member of Advisory Board	1.2yrs	no data	no data
Samintharaj Kumar	Member of Advisory Board	1.2yrs	no data	no data
James Tan	Member of Advisory Board	1.2yrs	no data	no data
GK Ananda	Member of Advisory Board	1.2yrs	no data	no data
Michael Keenan	Non-Executive Director	less than a year	AU$18.24k	no data

1.2yrs

Average Tenure

Experienced Board: OSX's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Osteopore Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 30, 2024

Osteopore Limited Announces Resignation of Deborah Ho as Joint Company Secretary

Osteopore Limited Announces Appointment of Kellie Davis as Joint Company Secretary, Effective 26 January 2023

Less than half of directors are independent

Insider recently bought AU$1.9m worth of stock

Recent updates

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 30, 2024

Osteopore Limited has filed a Follow-on Equity Offering in the amount of AUD 2.99532 million.

Full year 2023 earnings released: AU$0.031 loss per share (vs AU$0.51 loss in FY 2022)

New minor risk - Share price stability

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Osteopore Limited Announces Resignation of Deborah Ho as Joint Company Secretary

First half 2023 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in 1H 2022)

Full year 2022 earnings released: AU$0.034 loss per share (vs AU$0.031 loss in FY 2021)

Osteopore Limited Enters Orthopaedic Market in Great Britain

Osteopore Limited Announces Appointment of Kellie Davis as Joint Company Secretary, Effective 26 January 2023

Osteopore Limited (ASX:OSX) agreed to acquire Businesses Of Lomic Korea, 3D Aesthetic Solutions, 3D Healthcare Solutions And 3D Aesthetic Medical Lim Jae Hoon from Lim Jae Hoon for AUD2.05 million.

Less than half of directors are independent

First half 2022 earnings released: AU$0.017 loss per share (vs AU$0.012 loss in 1H 2021)

Insider recently bought AU$1.9m worth of stock

We Think Osteopore (ASX:OSX) Needs To Drive Business Growth Carefully

Osteopore Limited Announces Appointment of Dr. Lim Jing as Chief Operating Officer

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Osteopore Limited Announces Resignation of Vlado Bosanac as Non-Executive Director

High number of new and inexperienced directors

High number of new and inexperienced directors

First half 2021 earnings released: AU$0.012 loss per share (vs AU$0.007 loss in 1H 2020)

Non Executive Chairman Brett Sandercock has left the company

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

New 90-day low: AU$0.47

Osteopore Limited Announces A Cooperation Agreement with Terumo Blood and Cell Technologies

Osteopore International Collaborates with Maastricht University Medical Centre to Develop Implant Solution That Prevents Leg Amputations

New 90-day low: AU$0.50

How Many Osteopore Limited (ASX:OSX) Shares Have Insiders Sold, In The Last Year?

New 90-day low: AU$0.51

New 90-day high: AU$0.61

Osteopore Limited Signs Distribution Agreement with MTG Medizintechnik Göhl

Osteopore Limited Announce the Appointment of Carl Runde as Chief Financial Officer

First half earnings released

Osteopore Limited has completed a Follow-on Equity Offering in the amount of AUD 8.5 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure